204 related articles for article (PubMed ID: 33232755)
1. Effect of implant formation on drug release kinetics of in situ forming implants.
Suh MS; Kastellorizios M; Tipnis N; Zou Y; Wang Y; Choi S; Burgess DJ
Int J Pharm; 2021 Jan; 592():120105. PubMed ID: 33232755
[TBL] [Abstract][Full Text] [Related]
2. Novel adapter method for in vitro release testing of in situ forming implants.
Wang X; Bao Q; Suh MS; Kastellorizios M; Wang R; Burgess DJ
Int J Pharm; 2022 Jun; 621():121777. PubMed ID: 35489601
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA
Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
[TBL] [Abstract][Full Text] [Related]
4. In-situ forming PLGA implants: Towards less toxic solvents.
Ramos F; Willart JF; Neut C; Agossa K; Siepmann J; Siepmann F
Int J Pharm; 2024 May; 657():124121. PubMed ID: 38621617
[TBL] [Abstract][Full Text] [Related]
5. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
6. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
[TBL] [Abstract][Full Text] [Related]
7. Asenapine maleate in situ forming biodegradable implant: an approach to enhance bioavailability.
Avachat AM; Kapure SS
Int J Pharm; 2014 Dec; 477(1-2):64-72. PubMed ID: 25305379
[TBL] [Abstract][Full Text] [Related]
8. Improved small molecule drug release from in situ forming poly(lactic-co-glycolic acid) scaffolds incorporating poly(β-amino ester) and hydroxyapatite microparticles.
Fisher PD; Palomino P; Milbrandt TA; Hilt JZ; Puleo DA
J Biomater Sci Polym Ed; 2014; 25(11):1174-93. PubMed ID: 24903524
[TBL] [Abstract][Full Text] [Related]
9. Effect of injection site on in situ implant formation and drug release in vivo.
Patel RB; Solorio L; Wu H; Krupka T; Exner AA
J Control Release; 2010 Nov; 147(3):350-8. PubMed ID: 20728486
[TBL] [Abstract][Full Text] [Related]
10. Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure.
Solorio L; Exner AA
J Pharm Sci; 2015 Dec; 104(12):4322-4328. PubMed ID: 26506522
[TBL] [Abstract][Full Text] [Related]
11. An in vitro gel-based system for characterizing and predicting the long-term performance of PLGA in situ forming implants.
Li Z; Mu H; Weng Larsen S; Jensen H; Østergaard J
Int J Pharm; 2021 Nov; 609():121183. PubMed ID: 34653562
[TBL] [Abstract][Full Text] [Related]
12. Towards in vitro - In vivo correlation models for in situ forming drug implants.
Wang X; Roy M; Wang R; Kwok O; Wang Y; Wang Y; Qin B; Burgess DJ
J Control Release; 2024 Jun; ():. PubMed ID: 38936743
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive characterization of in situ forming implants using diagnostic ultrasound.
Solorio L; Babin BM; Patel RB; Mach J; Azar N; Exner AA
J Control Release; 2010 Apr; 143(2):183-90. PubMed ID: 20060859
[TBL] [Abstract][Full Text] [Related]
14. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
Sheshala R; Hong GC; Yee WP; Meka VS; Thakur RRS
Drug Deliv Transl Res; 2019 Apr; 9(2):534-542. PubMed ID: 29484530
[TBL] [Abstract][Full Text] [Related]
15. In-situ forming PLGA implants for intraocular dexamethasone delivery.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
[TBL] [Abstract][Full Text] [Related]
16. Release rate determination from in situ gel forming PLGA implant: a novel 'shape-controlled basket in tube' method.
Zhang Q; Fassihi R
J Pharm Pharmacol; 2020 Aug; 72(8):1038-1048. PubMed ID: 32342528
[TBL] [Abstract][Full Text] [Related]
17. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
18. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
Dong WY; Körber M; López Esguerra V; Bodmeier R
J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
[TBL] [Abstract][Full Text] [Related]
19. Drug release mechanisms of high-drug-load, melt-extruded dexamethasone intravitreal implants.
Costello MA; Liu J; Chen B; Wang Y; Qin B; Xu X; Li Q; Lynd NA; Zhang F
Eur J Pharm Biopharm; 2023 Jun; 187():46-56. PubMed ID: 37037387
[TBL] [Abstract][Full Text] [Related]
20. In-situ forming composite implants for periodontitis treatment: How the formulation determines system performance.
Do MP; Neut C; Metz H; Delcourt E; Mäder K; Siepmann J; Siepmann F
Int J Pharm; 2015; 486(1-2):38-51. PubMed ID: 25791762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
